You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

January 24, 2018

New Decree on Chemical Management and System for Chemical Declaration in Vietnam Benefits Chemical Trading Entities

Subscribe to Updates

On January 11, 2018, the National Single Window system for declaration of chemicals to be imported into Vietnam was officially launched. In its first week, this system was used and accessed by several major chemical companies who observed that the system was of very high quality, helping to complete the chemical declaration within a very short time. This extreme improvement comes on the heels of a new decree on chemical management in Vietnam.

Specifically, on October 9, 2017, the Government of Vietnam issued Decree No. 113/2017/ND-CP guiding the implementation of certain articles of the Law on Chemicals of 2007 (“Decree 113”). The new decree came into force on November 25, 2017, replacing Decree No. 108/2008 /ND-CP and Decree No. 26/2011/ND-CP, and addresses some limitations presented during the implementation of the previous decrees. Some of the key changes are detailed below.

National Single Window System

Certain chemicals imported into Vietnam must be declared with the Ministry of Industry and Trade (MOIT) before customs clearance. The previous chemical declaration process was done by filing paper forms (70% of all cases) or online (30%). Though paper filing was a time-consuming process and could affect the importing timeline, the online system suffered from difficulties in integrating digital signatures of the chemical trading entities, and the reports and information recorded in the online database were limited.

Decree 113 provides regulations regarding the aforementioned National Single Window system (Article 12.8), an online customs portal where traders can submit all documents and access all relevant information related to trade via a single electronic gateway, connecting customs with government agencies that deal with tax, immigration, quarantine, health, transport, agriculture, fisheries, foreign affairs, etc. The auto-reply from the MOIT is considered a declaration result which is shared with the importer and with customs before customs clearance (Article 27.4). As shown by the early results, this change should have a positive impact on the import activities of manufacturers, by providing a quick and simple procedure for the declaration of chemical importation.

Lists of Declared Chemicals

Decree 113 also provides the list of chemicals that must be declared before customs clearance. These chemicals are defined by their Vietnamese and English names, CAS (Chemical Abstracts Service) codes, HS (Harmonized System) codes, and chemical formulas. These details help chemical importers and customs agencies quickly input/verify the chemical information in the declaration form/customs form.

Chemical Extraction and Packaging

The government considers using, extracting, and packaging chemicals to be potentially high-risk activities. Articles 5.3 and 7 of Decree 113 provide regulations for extraction and packaging so that the adverse impacts on human health and the environment will be minimized. For example, chemical containers and packages are required to be tight, firm, and resistant to the chemicals themselves, weather, and normal handling impacts. The labels on the containers and packages must comply with regulations on chemical labeling. Used packages must be cleaned and stored separately.

National Chemical Inventory

Decree 113 emphasizes the importance of developing Vietnam’s National Chemical Inventory (a list of chemicals used in Vietnam under government regulations) and National Chemical Database for managing chemical safety, providing information for response systems, and providing information on hazardous chemicals in emergency situations. However, no detailed plan or timeline is provided.

 

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 24, 2024
Thailand’s Minister of Public Health recently promulgated the Ministerial Notification Re: Category 5 Narcotics Which Are Not Cannabis or Hemp Extract and Whose Consumption is Permitted for Treatment of Disease or for Research Purposes (2024). The notification took effect on April 23, 2024. The substances whose regulatory controls are affected by this new notification are psilocybin mushroom (Psilocybe cubensis (Earle) Singer), opium poppy (Papaver somniferum L. and Papaver bracteatum Lindl.), and other plants in these genera from which opium, opium alkaloids, psilocybin, or psilocin may be derived. As a result of this notification, these substances are now classified as category 5 narcotics that can be applied in medical treatment. Without the implementation of this notification, patients could not access newly developed medicines containing these substances, as Thailand’s Narcotic Code prohibits the possession and use of category 5 narcotics. Nonetheless, this does not mean that psilocybin mushrooms and opium can be used without any conditions. There is still a long process to go through before these substances can be used in medical treatment or clinical studies. Under the new notification, the FDA must first approve any medicinal drug formulation containing any of the above substances, and subsequently, the production must be approved for medical use or research purposes. The importation of medicinal drug formulations containing psilocybin mushrooms or opium is not allowed. This seemingly small regulatory change addresses the previous legal obstacle to the research and development of such medicines. According to the previous regulation, a physician or researcher could apply to the Thai FDA for a license to produce or possess medicines containing the aforementioned narcotics. However, production and consumption are considered different activities, and consuming a narcotic-containing medicine, even if it was produced under a valid license, is prohibited by the Narcotics Code and is punishable by imprisonment,
Read More
June 11, 2024
Advances in biotechnology have enabled the development of a range of new agricultural tools. From DNA sequencing to plant tissue culture and gene editing, these advances are facilitating the development of better crops. Genetically modified organisms (GMOs) are one well-known example of agricultural biotechnology. GMOs are organisms whose genetic material has been artificially altered by inserting a piece of foreign DNA. This DNA may be synthetic in origin or sourced from other organisms. Genome editing (also called gene editing or GEd) involves making precise changes to an organism’s genome without the integration of foreign DNA elements. Several approaches to genome editing have been developed. A well-known one is called CRISPR-Cas9, in which scientists make precise “cuts” in the DNA to create a new genetic variation. Unlike with GMOs, this introduces only minor modifications that are indistinguishable from natural mutations, typically by transplanting genes that code desirable traits from one species into another. GEd technology has been recognized and supported by the Food and Agriculture Organization of the United Nations (FAO). Thirteen FAO-member countries who are also members of the Organization for Economic Cooperation and Development (OECD) announced their support of the use of GEd technology for commercial uses and consumption at a recent WTO meeting. In addition, over 40 countries around the world, such as Argentina, Australia, Brazil, Canada, Chile, China, England, Japan, Kenya, the Philippines, Russia, the UK, and the US, have published policies emphasizing that foods free of transgenes (i.e., foods that do not contain genes transferred from external sources) are not GMOs, concluding that GEd plants are as safe as normal plants. In February 2024, the European Parliament approved new genomic techniques (NGTs), or GEd. As a result, plants that are produced using GEd technology are not classified by the EU as GMOs, and the EU
Read More
February 14, 2024
Thailand is preparing to implement new rules on drug importation for clinical studies. The Medicines Regulation Department of Thailand’s Food and Drug Administration (Thai FDA) first issued the Notification Re. Detailed Requirements for Drug Importation into Thailand for Clinical Studies almost a year ago, and the notification is expected to come into effect on March 1, 2024. Key Provisions The notification aims at enhancing the efficiency of conducting clinical studies while ensuring the protection of human subjects participating in such studies within Thailand. Some of its key provisions include: Definition of Clinical Study. The notification defines a “clinical study” as a study of a medicine involving human subjects, conducted to provide supporting evidence for the registration of a medicinal product in Thailand or other countries, including for additional indications or variations of a registration dossier. Compliance with ICH GCP. Clinical studies conducted in Thailand must adhere to the current edition of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines. Clinical Trial Application. Sponsors are required to submit a clinical trial application along with supporting documents to the Thai FDA for approval before commencing a clinical study. The permit remains valid for five years and is renewable. Supply of Investigational Drugs. Sponsors must obtain investigational drugs from manufacturers compliant with Good Manufacturing Practice (GMP) standards as recognized by the Thai FDA. Postapproval Obligations. The secretary-general of the Thai FDA may impose postapproval conditions or order investigators to conduct or suspend certain activities to ensure human subject protection and regulatory compliance. Regulatory Oversight. The Thai FDA is responsible for inspecting and overseeing the regulatory compliance of clinical studies, including during prestudy, ongoing, and poststudy phases. The Thai FDA may also conduct inspections of clinical studies conducted overseas. The Thai FDA
Read More
December 15, 2023
As part of its membership in Lex Mundi, Tilleke & Gibbins has published an updated edition of its Guide to Doing Business in Thailand for 2023. This guide outlines the key factors for starting and operating a business in the Thai market. Issues covered include: Investment incentives Financial facilities Exchange controls Import and export regulations Structures for doing business Requirements for the Establishment of a Business Operation of the Business Cessation or Termination of the Business Labor legislation, relations, and supply Tax Immigration requirements This publication is part of Lex Mundi’s Country Guides series prepared by member firms in more than 100 jurisdictions worldwide. The guides serve as a useful resource for planning international business strategy and researching new markets. The full Guide to Doing Business in Thailand is available through the button below.
Read More